GS-100 ngumutsi lohlanganisiwe we AAV9 lofaka i-NGLY1 yemuntfu. Utfole ligama lekutsi ngumutsi lolahlekile ku-US Food and Drug Administration kanye ne-European Medicine Agency (EMA). Lendlela yekwelapha iphindze yatfola ligama le-FDA's rare paediatric disease nga-2021 kanye ne-fast track designation ngemnyaka lophelile.